These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28383998)

  • 1. Effectiveness and Side Effect Profile of Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder in Youth with Epilepsy.
    Kral MC; Lally MD; Boan AD
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):735-740. PubMed ID: 28383998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
    Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management.
    Childress AC; Sallee FR
    CNS Drugs; 2014 Feb; 28(2):121-9. PubMed ID: 24402970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
    Mohammadi M; Akhondzadeh S
    Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
    Martens MA; Seyfer DL; Andridge RR; Foster JE; McClure KE; Coury DL
    Res Dev Disabil; 2013 May; 34(5):1700-9. PubMed ID: 23500164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.
    Gucuyener K; Erdemoglu AK; Senol S; Serdaroglu A; Soysal S; Kockar AI
    J Child Neurol; 2003 Feb; 18(2):109-12. PubMed ID: 12693777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.
    Rugino TA; Copley TC
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):230-5. PubMed ID: 11211372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients.
    Cornforth C; Sonuga-Barke E; Coghill D
    Curr Pharm Des; 2010; 16(22):2424-33. PubMed ID: 20513225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder.
    Chacko A; Pelham WE; Gnagy EM; Greiner A; Vallano G; Bukstein O; Rancurello M
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):249-57. PubMed ID: 15725969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.
    Firestone P; Musten LM; Pisterman S; Mercer J; Bennett S
    J Child Adolesc Psychopharmacol; 1998; 8(1):13-25. PubMed ID: 9639076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
    Leibson CL; Barbaresi WJ; Ransom J; Colligan RC; Kemner J; Weaver AL; Katusic SK
    Ambul Pediatr; 2006; 6(1):45-53. PubMed ID: 16443183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior treatment with stimulant medication: a much neglected confounder of studies of growth in children with attention-deficit/hyperactivity disorder.
    Poulton AS; Nanan R
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):385-7. PubMed ID: 18759649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.